Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 6/20 | 0.35 |
| ▸ | FNTB | P49356 | 6/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14646596 | 0.76 | NPY1R (0.44) | TNK2CYP19A1NPY1RNPY2RNPY4R | |
| SCHEMBL3551984 | 0.76 | TNK2 (0.35) | TNK2FNTAFNTBPGGT1BDHFR | |
| SCHEMBL3544130 | 0.76 | MEN1 (0.40) | CYP3A4TNK2FNTAFNTBPGGT1B | |
| SCHEMBL7231933 | 0.73 | NPY1R (0.54) | TNK2NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL4382295 | 0.73 | MEN1 (0.45) | TNK2NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL1457107 | 0.73 | NPY1R (0.43) | TNK2NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL3500438 | 0.71 | TNK2 (0.44) | TNK2NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL13350340 | 0.71 | MEN1 (0.39) | CYP3A4TNK2 | |
| SCHEMBL26840683 | 0.71 | NPY1R (0.41) | CYP3A4TNK2NPY1RNPY2RNPY4R | |
| SCHEMBL17694753 | 0.71 | ESR1 (0.46) | CYP3A4TNK2NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | CYP17A1 207/4885CYP3A4 151/4885TNK2 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.